Related Experiment Videos
Gene-directed enzyme prodrug therapy: a current assessment.
Stephanie R McKeown1, Claire Ward, Tracy Robson
1University of Ulster at Coleraine, Radiation Science Group, School of Biomedical Sciences, Centre for Molecular Biosciences, Cromore Road, Coleraine, Co Londonderry, Northern Ireland. S.R.McKeown@ulster.ac.uk
Current Opinion in Molecular Therapeutics
|October 8, 2004
Summary
Gene-directed enzyme prodrug therapy uses gene delivery for tumor-specific enzyme activation of prodrugs into cancer-killing agents. This review examines current preclinical and clinical enzyme-prodrug combinations and discusses tumor targeting and bystander effects.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Gene-directed enzyme prodrug therapy (GDEPT) offers targeted cancer treatment.
- It involves delivering a gene for a drug-metabolizing enzyme into tumor cells.
- This enables localized conversion of a non-toxic prodrug to a potent cytotoxic agent.
Purpose of the Study:
- To review current enzyme-prodrug combinations in GDEPT.
- To discuss the challenges and advancements in tumor specificity.
- To explore the potential of bystander effects for enhanced cytotoxicity.
Main Methods:
- Literature review of preclinical and clinical studies on GDEPT.
- Analysis of various enzyme-prodrug systems.
- Discussion of targeting strategies and efficacy metrics.
Main Results:
- Multiple enzyme-prodrug systems are under investigation.
- Tumor specificity remains a key challenge.
- Bystander effects show promise for improving treatment outcomes.
Conclusions:
- GDEPT is a promising strategy for targeted cancer therapy.
- Further research is needed to optimize tumor targeting and efficacy.
- The development of effective enzyme-prodrug combinations holds significant therapeutic potential.